Adsorbing/dissolving Lyoprotectant Matrix Technology for Non-cryogenic Storage of Archival Human Sera

Impact of ZIF-8, ArgHCl, and Ionic Liquid-Based Formulations on the Conformational and Colloidal Stability of Antibodies

Various formulations consisting of biomaterials zirconium imidazolate framework-8 (ZIF-8), choline acetate ([Ch][Ac]), and arginine hydrochloride (argHCl) are optimized to study the stability of antibody, Immunoglobulin G (IgG). We have performed several instrumentations including UV-visible spectroscopy, dynamic light scattering (DLS), circular dichroism (far UV CD), and atomic force microscopy (AFM) in the presence of all the formulations to investigate the conformational and colloidal stability of the antibodies. Alongside, the packing efficiency of all the formulations was also explored by storing IgG at 4 °C for 3 months. We have tried to investigate the interactions between biomaterials and antibodies with the motive of designing aggregation-resistant formulations. The overall stability of IgG was improved in the presence of [Ch][Ac]; however, ZIF-8 and argHCl cause relatively more aggregation, although the structure was retained in all the formulations. The key aspect of this study is that the presence of [Ch][Ac] increases ZIF-8@IgG's thermal stability and resistance to IgG-argHCl aggregation. All over, for the first time, with different experimental approaches, the impact of each biomaterial individually and in combination is explored to study their effect on the stability of antibodies. Thus, better efficient formulations can be designed for the storage/packaging of IgG-based drugs which ultimately will have more applicability in pharmaceuticals.

Dextranol: An inert xeroprotectant

Dextranol, a reduced dextran, prevents damage to stored dry protein samples that unmodified dextran would otherwise cause. Desiccation protectants (xeroprotectants) like the polysaccharide dextran are critical for preserving dried protein samples by forming a rigid glass that protects entrapped protein molecules. Stably dried proteins are important for maintaining critical information in clinical samples like blood serum as well as maintaining activity of biologic drug compounds. However, we found that dextran reacts with both dried serum proteins and lyophilized purified proteins during storage, producing high-molecular weight Amadori-product conjugates. These conjugates appeared in a matter of days or weeks when stored at elevated temperatures (37° or 45°C), but also appeared on a timescale of months when stored at room temperature. We synthesized a less reactive dextranol by reducing dextran's anomeric carbon from an aldehyde to an alcohol. Serum samples dried in a dextranol-based matrix protected the serum proteins from forming high-molecular weight conjugates. The levels of four cancer-related serum biomarkers (prostate specific antigen, neuropilin-1, osteopontin, and matrix-metalloproteinase 7) decreased, as measured by immunoassay, when serum samples were stored for one to two weeks in dextran-based matrix. Switching to a dextranol-based xeroprotection matrix slightly reduced the damage to osteopontin and completely stopped any detectable damage during storage in the other three biomarkers when stored for a period of two weeks at 45°C. We also found that switching from dextran to dextranol in a lyophilization formulation eliminates this unwanted reaction, even at elevated temperatures. Dextranol offers a small and easy modification to dextran that significantly improves the molecule's function as a xeroprotectant by eliminating the potential for damaging protein-polysaccharide conjugation.